

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/800,022	03/12/2004	Frederick F. VanGoor	VPI/03-103 US	6802
27916 7	7590 12/09/2005		EXAMINER	
VERTEX PHARMACEUTICALS INC.			KOSACK, JOSEPH R	
130 WAVERL	Y STREET E. MA 02139-4242		ART UNIT	PAPER NUMBER
Chimbiabas	, 1411 02137 1212		1626	
			DATE MAILED: 12/09/2005	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)			
		10/800,022	VANGOOR ET AL.			
Office Action Sum	mary	Examiner	Art Unit			
		Joseph Kosack	1626			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
WHICHEVER IS LONGER, FRC - Extensions of time may be available under after SIX (6) MONTHS from the mailing dat - If NO period for reply is specified above, the - Failure to reply within the set or extended p	M THE MAILING DA the provisions of 37 CFR 1.13 e of this communication. e maximum statutory period w eriod for reply will, by statute, hree months after the mailing	'IS SET TO EXPIRE 1 MONTH(ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim rill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE date of this communication, even if timely filed	 I. nely filed the mailing date of this communication. D (35 U.S.C. § 133). 			
Status						
1) Responsive to communication	• •					
2a) This action is FINAL .	\cdot					
- · · · · · · · · · · · · · · · · · · ·	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
closed in accordance with	the practice under E	х рапе Quayle, 1935 С.D. 11, 45	53 O.G. 213.			
Disposition of Claims						
4) Claim(s) 1-84 is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allow						
6) Claim(s) is/are reje						
7) Claim(s) is/are object		election requirement				
8) Claim(s) <u>1-84</u> are subject	to restriction and/or t	siection requirement.				
Application Papers						
9) ☐ The specification is objected	ed to by the Examine	r.				
10)☐ The drawing(s) filed on						
		drawing(s) be held in abeyance. Se				
Replacement drawing sheet(11) The oath or declaration is o		ion is required if the drawing(s) is ob caminer. Note the attached Office				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made a) All b) Some * c) □		priority under 35 U.S.C. § 119(a)-(d) or (f).			
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
•		rity documents have been receive	ed in this National Stage			
• •		u (PCT Rule 17.2(a)).	ad			
" See the attached detailed C	onice action for a list	of the certified copies not receive	su.			
Attachment(s)						
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawi 		4) Interview Summary Paper No(s)/Mail D				
Notice of Draftsperson's Patent Drawi Information Disclosure Statement(s) (I Paper No(s)/Mail Date	=		Patent Application (PTO-152)			

DETAILED ACTION

Claims 1-84 are pending in the instant application.

Election/Restrictions

The Markush Group set forth in the claims includes both independent and distinct inventions, and patentably distinct compounds (species) within each invention.

However, this application discloses and claims a plurality of patentably distinct inventions far too numerous to list individually. Moreover, each of these inventions contains a plurality of patentably distinct compounds, which are too numerous to list individually. For the reasons provided below, restriction to one of the following Groups is required under 35 U.S.C. § 121, wherein a Group is a set of patentable distinct inventions of a broad statutory category (e.g. compounds, methods of use, methods of making, etc.):

- I. Claims 1-48, drawn to methods of use of compounds of Formula I, classified in various subclasses of class 514, 540, 544, 546, 548, and 549.
- II. Claims 49 and 52-84, drawn to compounds of Formula I, classified in various subclasses of class 514, 540, 544, 546, 548, and 549.
- III. Claims 50-51, drawn to an item of manufacture including compounds of Formula I, classified in various subclasses of class 514, 540, 544, 546, 548, and 549.

In accordance with the decisions in *In re Harnisch*, 631 F.2d 716, 206 USPQ 300 (CCPA 1980); and *Ex parte Hozumi*, 3 USPQ2d 1059 (Bd. Pat. App. & Int. 1984), restriction of a Markush Group is proper where the compounds within the group either

Application/Control Number: 10/800,022 Page 3

Art Unit: 1626

(1) do not share a common utility, or (2) do not share a substantial structural feature disclosed as being essential to that utility. In addition, a Markush Group may encompass a plurality of independent and distinct inventions where two or more members are so unrelated and diverse that a prior art reference anticipating the claim with respect to one of the members would not render the other member(s) obvious under 35 U.S.C. § 103.

Where an election of Groups II or III is made, an election of a single compound is further required including an exact definition of each substitution on the base molecule, wherein a single member at each substituent group or moiety is selected. For example, if a base molecule has a substituent group Y, wherein Y is recited to be any one of halo, CN, NO2, CHF2, CH2F, etc., then Applicant must select a single substituent of Y, for example CN, and each subsequent variable position, i.e. A, B, C, X, etc...

Where an election of Group I is made, an election of a specific method of use along with an elected compound of Formula 1 is required. For example, if Group I were elected, Applicant would choose a method for treating:

- A. Dry Eve Disease:
- B. Anemia;
- C. Asthma;
- D. Male Infertility;
- E. Emphysema;
- F. Etc.

with an elected compound of Formula 1 as described above.

In the instant case, upon election of a single compound the Office will review the claims and disclosure to determine the scope of the independent invention encompassing the elected compound (compounds that are so similar thereto as to be within the same inventive concept and reduction to practice). The scope of an independent invention will encompass all compounds within the scope of the claim, which fall into the same class and subclass as the elected compound, but may also include additional compounds, which fall in related subclasses.

Examination will then proceed on the elected compound as defined by common classification AND the entire scope of the invention encompassing the elected compound as defined by common classification. A clear statement of the examined invention, defined by those class(es) and subclass(es) will be set forth in the first action on the merits. Note that the restriction requirement will not be made final until such time as applicant is informed of the full scope of compounds along with (if appropriate) the process of using or making said compound under examination. This will be set forth by reference to specific class(es) and subclass(es) examined.

Should applicant traverse on the ground that the compounds are not patentably distinct, applicant should submit evidence or identity such evidence now of record showing the compound to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in rejection under 35 U.S.C. § 103(a) of the other.

All compounds falling outside the class(es) and subclass(es) of the selected compound and any other subclass encompassed by the election above will be directed to nonelected subject matter and will be withdrawn from consideration under 35 U.S.C. § 121 and 37 C.F.R. 1.142(b). Applicant may reserve the right to file divisional applications on the remaining subject matter. (The provisions of 35 U.S.C. § 121 apply with regard to double patenting covering divisional applications.)

Applicant is reminded that upon cancellation of claims to a nonelected invention, the inventions must be amended in compliance with 37 C.F.R. 1.48(b) if one of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 C.F.R. 1.48(b) and by the fee required under 37 C.F.R. 1.17(i).

If desired upon election of a single compound, applicant can review the claims and disclosure to determine the scope of the invention and can set forth a group of compounds which are so similar, within the same inventive concept and reduction to practice. Markush claims must be provided with support in the disclosure for each member of the Markush group. See MPEP 608.01(p). Applicant should exercise caution in making a selection of a single member for each substituent group on the base molecule to be consistent with the written description.

Rational Establishing Patentable Distinctiveness Within Each Group

Each Group listed above is directed to or involves the use of compounds which are recognized in the art as being distinct from one another because of their diverse chemical structure, their different chemical properties, modes of action, different effects

and reactive conditions (MPEP 806.04, MPEP 808.01). Additionally, the level of skill in the art is not such that one invention would be obvious over the other invention (Group), i.e. they are presumed patentable over each other. Chemical structures that are similar are presumed to function similarly, whereas chemical structures that are not similar are not presumed to be function similarly. The presumption even for similar chemical structures though is not irrebuttable, but may be overcome by scientific reasoning or evidence showing that the structure of the prior art would not have been expected to function as the structure of the claimed invention. Note that in accordance with the holding of *Application of Papesch*, 50 CCPA 1084, 315 F.2d 381, 137 USPQ 43 (CCPA 1963) and *In re Lalu*, 223 USPQ 1257 (Fed. Cir. 1984), chemical structures are patentably distinct where the structures are either not structurally similar, or the prior art fails to suggest a function of a claimed compound would have been expected from a similar structure.

The above groups represent general areas wherein the inventions are independent and distinct, each from the other because of the following reasons:

Inventions I and II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the method of treating anemia can be accomplished by using an iron supplement instead of the product of Invention II.

Invention III is independent and distinct from each of Invention I and II because they are directed to different statutory classes of invention, and the practice of one of Invention I or II or III would not result in the practice of the other Invention, i.e., making the compound of Formula I is not a process that makes an article of manufacture.

In addition, because of the plethora of classes and subclasses in each of the Inventions, a serious burden is imposed on the examiner to perform a complete search of the defined areas. Therefore, because of the reasons given above, the restriction set forth is proper and not to restrict would impose a serious burden in the examination of this application.

Advisory of Rejoinder

The following is a recitation of MPEP 821.04, Rejoinder:

Where product and process claims drawn to independent and distinct inventions are presented in the same application, applicant may be called upon under 35 U.S.C. 121 to elect claims to either the product or process. See MPEP § 806.05(f) and § 806.05(h). The claims to the nonelected invention will be withdrawn from further consideration under 37 CFR 1.142. See MPEP § 809.02(c) and § 821 through § 821.03. However, if applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims, which depend from or otherwise include all the limitations of the allowable product claim will be rejoined.

Where the application as originally filed discloses the product and the process for making and/or using the product, and only claims directed to the product are presented for examination, when a product claim is found allowable, applicant may present claims directed to the process of making and/or using the patentable product by way of amendment pursuant to 37 CFR 1.121. In view of the rejoinder procedure, and in order to expedite prosecution, applicants are encouraged to present such process claims, preferably as dependent claims, in the application at an early stage of prosecution. Process claims, which depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance. Amendments submitted after final rejection are governed by 37 CFR 1.116. Process claims which do not depend from or otherwise include the limitations of the patentable product will be withdrawn from consideration, via an election by original presentation (see MPEP § 821.03). Amendments submitted after allowance are governed by 37 CFR 1.312. Process claims which depend from or otherwise include all the limitations of an allowed product claim and which meet the requirements of 35 U.S.C. 101, 102, 103, and 112 may be entered.

Application/Control Number: 10/800,022

Art Unit: 1626

Where product and process claims are presented in a single application and that application qualifies under the transitional restriction practice pursuant to 37 CFR 1.129(b), applicant may either: (A) elect the invention to be searched and examined and pay the fee set forth in 37 CFR 1.17(s) and have the additional inventions searched and examined under 37 CFR 1.129(b)(2); or (B) elect the invention to be searched and examined and not pay the additional fee (37 CFR 1.129(b)(3)). Where no additional fee is paid, if the elected invention is directed to the product and the claims directed to the product are subsequently found patentable, process claims which either depend from or include all the limitations of the allowable product will be rejoined. If applicant chooses to pay the fees to have the additional inventions searched and examined pursuant to 37 CFR 1.129(b)(2) even if the product is found allowable, applicant would not be entitled to a refund of the fees paid under 37 CFR 1.129(b) by arguing that the process claims could have been rejoined. 37 CFR 1.26(a) states that "[T]he Commissioner may refund any fee paid by mistake or in excess of that required. A change of purpose after the payment of a fee...will not entitle a party to a refund of such fee..." In this case, the fees paid under 37 CFR 1.129(b) were not paid by mistake nor paid in excess, therefore, applicant would not be entitled to a refund. In the event of rejoinder, the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101,102, 103, and 112. If the application containing the rejoined claims is not in condition for allowance, the subsequent Office action may be made final, or, if the application was already under final rejection, the next Office action may be an advisory action. Form paragraphs 8.42 through 8.44 should be used to notify applicant of the rejoinder of process claims which depend from or otherwise include all the limitations of an allowable product claim.

In the event of rejoinder, the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104 - 1.106. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. If the application containing the rejoined claims is not in condition for allowance, the subsequent Office action may be made final, or, if the application was already under final rejection, the next Office action may be an advisory action.

The following is a recitation from paragraph five, "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai*, *In re Brouwer* and 35 U.S.C. §103(b)" (1184 TMOG 86(March 26, 1996)):

"However, in the case of an elected product claim, rejoinder will be permitted when a product claim is found allowable and the withdrawn process claim **depends from or otherwise includes all the limitations of** an allowed product claim. Withdrawn process claims not commensurate in scope with an allowed product claim will not be rejoined." (emphasis added)

Pursuant to MPEP § 821.04 and *In re Ochiai*, 71 F.3d 1565, 37 USPQ 1127 (Fed. Cir. 1995), rejoinder of product claims with process claims commensurate in scope with the allowed product claims will occur following a finding that the product

claims are allowable. Until such time, a restriction between product claims and process claims is deemed proper. Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution to maintain either dependency on the product claims or to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder.

A telephone call was made to Nandakumar Govindaswamy on December 6, 2005 to request an oral election to the above restriction requirement, but did not result in an election being made.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Joseph Kosack whose telephone number is (571)-272-5575. The examiner can normally be reached on M-F 7:15-3:45.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph McKane can be reached on (571)-272-0699. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/800,022 Page 10

Art Unit: 1626

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Joseph Kosack Patent Examiner

Patent Examine Art Unit 1626 KAMAL A. SAEED, PH 1
PRIMARY EXAMEN

Joseph K. McKane

Supervisory Patent Examiner

Art Unit 1626